pual,
I've wondered the same thing given the US trial appears to be delayed a full year - which horrible news unless the FDA gives us a late suprise, which I doubt. I don't think the market is aware of that yet or how long it will take for this drug to be on the market in the US.
Also, the company missed ANOTHER deadline by not having cuv9900 started in Q1. So that is even more disappointment from this mgmt team.
Trial data from PLE and EPP Phase III confirmatory study in Europe are not going to be out before Q3, so this sudden jump is odd. It could be positioning for a possible runup to Phase III EPP results data. But it's pretty early for that runup.
Still many months before they even file in Europe.
Very unimpressed with these guys.
afr article re cuv, page-5
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |